Currax v. Taro Pharmaceuticals: 10-Patent Silenor Dispute Dismissed Without Prejudice
Currax Pharmaceuticals filed suit in the District of New Jersey asserting 10 patents covering Silenor (doxepin hydrochloride) 3 mg and 6 mg tablets against Taro Pharmaceutical Industries and its U.S. affiliates. After 263 days, the court dismissed all claims, counterclaims, and defenses without prejudice — leaving every substantive issue unresolved and the door open to re-litigation.
A 10-patent ANDA showdown over Silenor ends before it begins
On 1 July 2024, Currax Pharmaceuticals, LLC — the holder of NDA No. 022036 for Silenor (doxepin hydrochloride) tablets in 3 mg and 6 mg strengths — filed a Hatch-Waxman infringement action in the U.S. District Court for the District of New Jersey against Taro Pharmaceutical Industries Limited, Taro Pharmaceuticals U.S.A., Inc., and Taro Pharmaceuticals, Inc. The complaint asserted ten issued U.S. patents spanning multiple application lineages, collectively covering formulations, compositions, and methods of use relating to low-dose doxepin hydrochloride for sleep maintenance insomnia.
On 21 March 2025, the district court disposed of the case by dismissing each of the parties’ claims, counterclaims, and defenses without prejudice — a termination that carries no res judicata bar and leaves both sides free to re-file or renegotiate. No merits determination was made on infringement, validity, or enforceability of any of the ten asserted patents. The without-prejudice character of the dismissal is significant: Taro’s ANDA filing remains live unless separately withdrawn, and the 30-month Hatch-Waxman stay implications may require separate analysis depending on the filing chronology.
The 263-day duration — well short of the 18-to-30-month window typically required to reach trial in complex ANDA matters — suggests the parties likely resolved their immediate commercial differences through negotiation, a licensing arrangement, or a consent-based stay, though the public record is silent on the specific terms. The breadth of the patent portfolio asserted (ten patents across multiple continuation lineages) and the involvement of three Taro entities are consistent with a strategic enforcement posture designed to trigger the 30-month stay; the without-prejudice exit leaves that strategic calculus unresolved for outside observers.
Filing to Dismissed without Prejudice in 263 days
263 days from filing to dismissal — typical ANDA Hatch-Waxman first-instance timelines run 18–30 months to trial
Dismissed without prejudice: what the termination means for both sides
Without prejudice: no bar to re-filing
A dismissal without prejudice extinguishes the current action but imposes no res judicata effect. Neither party’s substantive rights are adjudicated. Currax may re-assert any or all of its ten patents in a new action; Taro may re-plead invalidity or non-infringement counterclaims. The dismissal order’s scope — covering ‘claims, counterclaims and defenses’ — confirms the parties jointly sought a clean slate rather than a one-sided withdrawal.
No merits rulingCurrax retains full enforcement rights across all 10 patents
Because the dismissal is without prejudice and no invalidity ruling was entered, all ten Silenor patents remain enforceable on their face. Currax can pursue Taro — or any other ANDA filer — in a subsequent action. The absence of a merits ruling also means no adverse claim-construction record was established, preserving Currax’s interpretive positions for future litigation. A licensing or settlement side agreement may govern the commercial relationship, but none is publicly disclosed.
Patents intact and re-assertableTaro faces no injunction — but no cleared path to market either
Taro secured no court-endorsed invalidity or non-infringement finding. Any FDA tentative or final approval of Taro’s ANDA remains subject to patent-exclusivity periods unless a separate agreement with Currax governs launch timing. The without-prejudice dismissal leaves Taro exposed to re-suit if it attempts a commercial launch before patent expiry or absent a licence. The public record does not disclose whether a covenant-not-to-sue or market-entry date was agreed.
No cleared path confirmedSilenor exclusivity picture remains opaque for payers and competitors
With no validity or infringement ruling, third-party ANDA filers and payers cannot rely on this case to forecast generic entry timing for doxepin HCl 3 mg/6 mg tablets. The ten-patent portfolio, spanning formulation and method-of-use claims, continues to represent a meaningful litigation risk for any generic entrant. Insurers and formulary managers monitoring Silenor substitution options should note that the without-prejudice exit does not signal imminent generic availability.
Generic timeline uncertainFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Currax Pharmaceuticals, LLC | Company | Specialty pharma company — holder of Silenor NDA and 10 doxepin HCl patentsSearch in Eureka ↗ |
| Defendant | TARO PHARMACEUTICAL INDUSTRIES LIMITED | Company | Generic pharmaceutical manufacturer and U.S. affiliates seeking ANDA approval for doxepin HCl tabletsSearch in Eureka ↗ |
| Co-Defendant | Taro Pharmaceuticals U.S.A., Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Taro Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Hector Daniel Ruiz | Attorney | Counsel for Currax Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Jessica K. Formichella | Attorney | Counsel for Currax Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for Currax Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Selena Miriam Ellis | Attorney | Counsel for Currax Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff law firm | DEMANT | Law Firm | Representing Currax Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’reilly Falanga, LLP | Law Firm | Representing Currax Pharmaceuticals, LLCSearch in Eureka ↗ |
| Defendant counsel | Gregory D. Miller | Attorney | Counsel for TARO PHARMACEUTICAL INDUSTRIES LIMITEDSearch in Eureka ↗ |
| Defendant counsel | MARCUS O. TUBIN | Attorney | Counsel for TARO PHARMACEUTICAL INDUSTRIES LIMITEDSearch in Eureka ↗ |
| Defendant counsel | Timothy P. Gonzalez | Attorney | Counsel for TARO PHARMACEUTICAL INDUSTRIES LIMITEDSearch in Eureka ↗ |
| Defendant law firm | Rivkin Radler LLP | Law Firm | Representing TARO PHARMACEUTICAL INDUSTRIES LIMITEDSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The termination order’s phrasing — ‘each of the parties’ claims, counterclaims and defenses are dismissed without prejudice’ — is notable for its symmetry. By capturing Taro’s counterclaims (typically invalidity and non-infringement) alongside Currax’s infringement claims, the order ensures no partial ruling survives. No claim construction, no validity finding, and no infringement determination was entered. The breadth of the without-prejudice dismissal is consistent with a negotiated exit where both sides preferred a clean slate over any court-endorsed position that could prejudice future dealings.
Silenor Patent Portfolio — 10 doxepin HCl formulation and method-of-use patents
The ten asserted patents — anchored by US7915307B2 (filed July 2007) and extending through US11110074B2 (filed May 2020) — collectively form a layered portfolio protecting Silenor, Currax’s branded low-dose doxepin hydrochloride product approved for sleep maintenance insomnia at 3 mg and 6 mg. The portfolio spans composition claims, formulation claims, and method-of-use claims, with multiple continuation families reflecting iterative prosecution designed to maintain coverage as the product matured commercially. Doxepin itself is a decades-old tricyclic compound, making the patent strategy dependent on novel formulation and dosing innovations rather than the active molecule.
The breadth of this portfolio — ten granted patents across more than a decade of prosecution — reflects a classic branded pharmaceutical lifecycle management strategy and creates a significant litigation risk for any generic entrant seeking Paragraph IV certification. For competitors in the insomnia therapeutic space, the co-existence of composition and method-of-use claims across distinct lineages means that design-around is non-trivial: clearing one family may leave exposure under another. The without-prejudice dismissal means every patent in this portfolio retains its full presumption of validity and remains available for assertion against Taro or any other ANDA filer.
Should you run an FTO against the Silenor doxepin patent portfolio?
Any company developing, formulating, or seeking regulatory approval for a doxepin hydrochloride oral tablet product at 3 mg or 6 mg dosage strengths should treat this ten-patent portfolio as a live enforcement risk. The without-prejudice dismissal in this case provides no cleared-claim precedent. R&D teams exploring low-dose doxepin formulations, alternative sleep indications, or extended-release variants should conduct a full FTO mapping across all ten patent families — including continuation and divisional applications that may still be pending — before committing to formulation development or ANDA filing.
PatSnap Eureka’s FTO Search Agent can map each of the ten Silenor patent families, identify claim-by-claim overlap with your proposed formulation, flag pending continuations, and surface prior art relevant to invalidity arguments. Because doxepin HCl is a compound with deep prior art, Eureka’s AI-assisted claim analysis can help distinguish which claims present the highest invalidity risk versus which are most defensively robust — enabling your team to prioritise design-around efforts or freedom-to-operate opinions with precision.
Run a freedom-to-operate analysis on US9107898B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA cases involving doxepin and sleep disorder patents
Explore related patent infringement actions in the D.N.J. involving doxepin HCl formulations, ANDA filings, and branded sleep therapeutic portfolios.
What this case signals for the Hatch-Waxman and specialty pharma IP landscape
A 10-patent ANDA suit dismissed in under nine months — without prejudice — raises pointed questions about settlement economics and portfolio strategy in branded sleep therapeutics.
Without-prejudice ANDA exits are often licensing proxies — read the silence carefully
When a multi-patent Hatch-Waxman case closes this quickly without a public consent judgment, it typically signals a confidential licence or launch-date agreement. IP teams monitoring doxepin HCl competitive dynamics should treat the dismissal as a potential trigger for a delayed generic entry, not an open door — and watch for Taro ANDA approval notices.
Ten-patent portfolios create asymmetric settlement leverage for branded pharma
Asserting ten patents across multiple continuation families — as Currax did here — is a deliberate litigation strategy. Each patent represents a separate invalidity burden for the generic. In settlement negotiations, the breadth of the portfolio typically extracts longer exclusivity windows or royalties. Companies building or acquiring branded pharma assets should note the value of deep continuation coverage in formulation and method-of-use spaces.
Currax v TARO — key questions answered
Currax asserted ten U.S. patents: US7915307B2, US8513299B2, US9107898B2, US9486437B2, US9572814B2, US9861607B2, US10238620B2, US10653660B2, US10653662B2, and US11110074B2 — all covering Silenor (doxepin hydrochloride) 3 mg and 6 mg tablet formulations and methods of use for sleep maintenance insomnia.
A dismissal without prejudice means no merits determination was made on infringement, invalidity, or enforceability of any of the ten patents. Both parties retain their full legal positions: Currax can re-assert the patents in a new action, and Taro can re-plead invalidity or non-infringement counterclaims. The dismissal does not signal that Taro’s ANDA is cleared for commercial launch.
The 263-day duration is significantly shorter than the typical 18-to-30-month window for complex ANDA cases to reach trial. This suggests the parties likely reached a negotiated resolution — potentially a licensing agreement, consent-based stay, or agreed market-entry date — though the public record does not disclose specific terms. The without-prejudice framing is consistent with a confidential side agreement.
Not necessarily. The without-prejudice dismissal provides no court-endorsed invalidity or non-infringement finding. Taro’s ANDA remains subject to Silenor’s patent exclusivity periods unless a separate launch-date agreement exists. The ten-patent portfolio retains its full presumption of validity. Third-party payers and formulary managers should not treat this dismissal as a reliable indicator of imminent generic availability.
The case was filed on 1 July 2024 and adjudicated in the U.S. District Court for the District of New Jersey (Case No. 1:24-cv-07446). The District of New Jersey is a primary venue for Hatch-Waxman ANDA litigation given New Jersey’s concentration of pharmaceutical companies. The case closed on 21 March 2025 via dismissal without prejudice.
PatSnap Eureka searches patents and litigation data to answer instantly.